Karunya Kandimalla, PhD

Associate Professor, Department of Pharmaceutics

Karunya Kandimalla

Contact Info

kkandima@umn.edu

Office Phone 612-624-3715

Fax 612-626-2125

Office Address:
Room 9-149A
Weaver-Densford Hall

Mailing Address:
University of Minnesota
College of Pharmacy
Department of Pharmaceutics
Room 9-177 WDH
308 Harvard St. SE
Minneapolis, MN 55455

Associate Professor, Department of Pharmaceutics


PhD of Pharmaceutics, University of Iowa

Master of Pharmaceutics, Florida A&M University

Bachelor of Pharmacy, Gulbarga University

Summary

Awards & Recognition

  • 2010 Florida A&M University Emerging Researcher Award.
  • Travel award to attend 11th RCMI International Symposium on Health Disparities, Honolulu, HI.
  • Graduate student Ms. Kristen Jaruszewski’s poster was awarded 3rd place in Moving Targets Seminar organized by the University of Southern California during AAPS 2009 conference at Los Angeles November 8-11, 2009.
  • Graduate student Ms. Kristen Jaruszewski was the recipient of the Best Poster Award in Life Sciences at the 2008 FAMU Student Research Forum, Florida A&M University, Tallahassee, FL.
  • Graduate student Mr. Edward Agyare was the recipient of the 2007 Graduate Research Association of Students in Pharmacy (GRASP) Outstanding Poster Award.
  • Graduate Symposium Award in Pharmaceutics, Drug Delivery and Pharmaceutical Technology, AAPS annual meeting 2003, Salt Lake City, UT (awarded for outstanding graduate research work).
  • Meritorious mention in life sciences, Oral presentation, James F. Jakobsen Research Forum 2003, University of Iowa, Iowa City, IA.
  • Award of excellence, oral presentation, Pharmaceutics Graduate Student Research Meeting (PGSRM) 2002, University of Nebraska Medical Center, Omaha, NE.
  • Best poster presentation, Minority Biomedical Research Support Symposium 1997, Tallahassee, FL.

Research

Research Summary/Interests

  • Delivery of therapeutic and diagnostic agents to the central nervous system
  • Nanomedicine
  • Cellular pharmacokinetics
  • Protein biophysics
  • Pharmacokinetic data analysis and modeling

Publications

  • Chitosan enhances the cellular uptake of poly lactic-co-glycolic acid nanoparticles and serves as a cryoprotectant. K.M. Jaruszewski, S. Ramakrishnan, J.F. Poduslo and K.K. Kandimalla (submitted).
  • Pharmacokinetics of novel MRI contrast agent in the brain of Alzheimer's disease transgenic mice. K.K. Kandimalla, T.M. Wengenack, G.L. Curran, C.R. Jack, M. Garwood and J.F. Poduslo (submitted).
  • Differences in the transport and accumulation of native and Dutch variant human amyloid-beta 40 at the blood-brain barrier: insights into physiological processes that promote cerebral amyloid angiopathy. E.K. Agyare, S. Fulzele, C.C. Yu, G.L. Curran, J.F. Poduslo and K K. Kandimalla (in review).
  • Role of nanotechnology in the diagnosis and treatment of Alzheimer’s disease. R.S. Omtri, K M. Jaruszewski and K.K. Kandimalla. Nanotechnology in Medicine (Mark Slevin, Editor) (2010).
  • HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/ hippocampal neurons. J.F. Poduslo, E.J. Gilles, M. Ramakrishnan, K.G. Howell, T.M. Wengenack, G.L. Curran and K.K. Kandimalla. PLoS One 5: e8813 (2010).
  • Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaquebinding monoclonal antibodies. M. Ramakrishnan, K.K. Kandimalla, T.M. Wengenack, K.G. Howell and J.F. Poduslo. Biochemistry 48: 10405-10415 (2009).
  • Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. K.K. Kandimalla, O.G. Scott, S. Fulzele, M.W. Davidson and J.F. Poduslo. PLoS One 4: e4627 (2009).
  • Biphasic flux profiles of melatonin: The Yin-Yang of transdermal permeation enhancement mediated by fatty alcohol enhancers. K.K. Kandimalla, R.J. Babu and M. Singh. Journal of Pharmaceutical Sciences 99: 209-218 (2010).
  • Development of a smart nano-vehicle to target cerebrovascular amyloid deposits observed in Alzheimer’s disease and vascular dementia. E.K. Agyare, C.C. Yu, G L. Curran, J.F. Poduslo and K.K. Kandimalla. Pharmaceutical Research 25: 2674-2684 (2008).
  • Selective T1-weighted enhancement of individual Alzheimer’s disease amyloid plaques using an antibody fragment against Abeta as a magnetic resonance molecular imaging contrast agent. M. Ramakrishnan, T.M. Wengenack, G.L. Curran, E.J. Gilles, M. Ramirez-Alvarado, K.K. Kandimalla, M. Garwood, C.J. Jack and J.F. Poduslo. Pharmaceutical Research 25: 1861-1872 (2008).
  • In vivo targeting of a novel peptide based magnetic resonance contrast agent to image individual amyloid plaques in Alzheimer’s disease transgenic mice. K.K. Kandimalla, T.M. Wengenack, G.L. Curran, E.J. Gilles and J.F. Poduslo. Journal of Pharmacology and Experimental Therapeutics 322: 541-549 (2007).
  • In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques. J.F. Poduslo, S.S. Holasek, M. Ramakrishnan, M. Ramirez-Alvarado, K.K. Kandimalla, E.J. Gilles, G.L. Curran and T.M. Wengenack. Journal of Neurochemistry 102: 420-433 (2007).
  • Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid ?40. K.K. Kandimalla, G.L. Currun, S.S. Holasek, E.J. Gilles, T.M. Wengenack, M. Ramirez-Alvarado and J.F. Poduslo. Journal of Pharmacology Experimental Therapeutics 318: 17-25 (2006).
  • Transport of hydroxyzine and triprolidine across bovine olfactory mucosa: role of passive diffusion in the direct noseto-brain uptake of small molecules. K.K. Kandimalla and M.D. Donovan. International Journal of Pharmaceutics 302: 133-144 (2005).
  • Localization and differential activity of P-glycoprotein in bovine olfactory and respiratory mucosae. K.K. Kandimalla and M.D. Donovan. Pharmaceutical Research 22: 1121-1128 (2005).
  • Activation of stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. S.S. Holasek, T.M. Wengenack, K.K. Kandimalla, C. Montano, D.M. Gregor, G.L. Curran and J.F. Poduslo. Brain Research 1045: 185-198 (2005).
  • Pharmacokinetic analysis of the blood-brain barrier transport of 125I-A 40 in wild type and Alzheimer’s disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. K.K. Kandimalla, G.L. Curran, S.S. Holasek, E.J. Gilles, T.M. Wengenack and J.F. Poduslo. Journal of Pharmacology and Experimental Therapeutics 313: 1370-1378 (2005).
  • Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine nasal mucosa: Implications on noseto-brain transport. K.K. Kandimalla and M.D. Donovan. Journal of Pharmaceutical Sciences 94: 613-624 (2005).
  • Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. N. Kanikkannan, K.K. Kandimalla, S.S. Lamba and M. Singh. Current Medicinal Chemistry 7: 593-608 (2000).
  • Effect of fatty acids on the permeation of melatonin across rat and pig skins in-vitro and on the transepidermal water loss in rats in-vivo. K.K. Kandimalla, N. Kanikkannan, S. Andega and M. Singh. Journal of Pharmacy and Pharmacology 51: 783-790 (1999).
  • Optimization of a vehicle mixture for the transdermal delivery of melatonin using artificial neural networks and response surface method. K.K. Kandimalla, N. Kanikkannan and M. Singh. Journal of Controlled Release 61: 71-82 (1999).